ShareCompartir
Volume 11, Number 8—August 2005
Research
Methicillin-resistant Staphylococcus aureus, Hawaii, 2000–2002
Fenfang Li*
, Sarah Y. Park†, Tracy L. Ayers†, F. DeWolfe Miller*, Ralph MacFadden†, Michele Nakata†, Myra Ching Lee†, and Paul V. Effler†
, Sarah Y. Park†, Tracy L. Ayers†, F. DeWolfe Miller*, Ralph MacFadden†, Michele Nakata†, Myra Ching Lee†, and Paul V. Effler†
Table 3
Resistance patterns of MRSA isolates from pediatric and adult patients by clinical setting, Hawaii, 2000–2002*
| Antimicrobial drug | Pediatric patients |
Adult patients |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Outpatients |
Inpatients |
Outpatients |
Inpatients |
|||||||
| No. isolates tested* | No. (%) resistant | No. isolates tested* | No. (%) resistant | p value† | No. isolates tested* | No. (%) resistant | No. isolates tested* | No. (%) resistant | p value† | |
| Ciprofloxacin | 604 | 11 (2) | 110 | 10 (9) | <0.01 | 1,502 | 545 (36) | 1,305 | 1,071 (85) | <0.01 |
| Clindamycin | 1,083 | 71 (7) | 202 | 39 (19) | <0.01 | 3,936 | 1,462 (37) | 2,830 | 2,128 (75) | <0.01 |
| Erythromycin | 1,092 | 261 (24) | 203 | 78 (38) | <0.01 | 4,018 | 2,186 (54) | 2,859 | 2,412 (84) | <0.01 |
| Gentamicin | 997 | 9 (1) | 199 | 12 (6) | <0.01 | 3,289 | 418 (13) | 2,609 | 906 (35) | <0.01 |
| Levofloxacin | 215 | 5 (2) | 59 | 9 (16) | <0.01 | 629 | 245 (39) | 549 | 433 (79) | <0.01 |
| Rifampin | 1,028 | 4 (0) | 199 | 5 (3) | <0.01 | 3,773 | 134 (4) | 2,795 | 355 (13) | <0.01 |
| Tetracycline | 812 | 27 (3) | 178 | 16 (9) | <0.01 | 3,414 | 667 (20) | 2,622 | 976 (37) | <0.01 |
| Trimethoprim/sulfamethoxazole | 1,092 | 1 (0) | 203 | 2 (1) | NS | 4,035 | 199 (5) | 2,862 | 278 (10) | <0.01 |
| Vancomycin | 1,092 | 0 (0) | 203 | 0 (0) | NA | 4,036 | 0 (0) | 2,865 | 0 (0) | NA |
*The number of MRSA isolates tested against each antimicrobial drug varies in each laboratory because the drug panel used differed for each MRSA. MRSA, methicillin-resistant Staphylococcus aureus; NS, not significant; NA, not applicable.
†By chi-square test comparing outpatients to inpatients within each patient group. Fisher exact test was used for rifampin within the pediatric population.
- Page created: April 23, 2012
- Page last updated: April 23, 2012
- Page last reviewed: April 23, 2012
- Centers for Disease Control and Prevention,
-
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)